Retraction Notice: Comprehensive Multi-Omics Investigation of Genomic Profiles

Overview

The article has been retracted due to concerns regarding data integrity, specifically similarities detected in multiple figures. The authors did not respond to inquiries from the publisher, leading to a loss of confidence in the findings.

Background

Lung adenocarcinoma (LUAD) is a leading cause of cancer-related mortality. The integrity of published research is crucial for advancing clinical knowledge and ensuring patient safety. Retractions highlight the importance of data verification in scientific studies.

Data Highlights

No numerical or trial data is available due to the retraction of the article.

Key Findings

• The article was retracted due to data integrity concerns.
• Similarities were noted in figures that raised questions about the validity of the results.
• The authors did not respond to the publisher's inquiries regarding these concerns.
• The retraction reflects the importance of data verification in scientific research.

Clinical Implications

Healthcare professionals should be aware of the retraction and its implications for the reliability of the findings presented.

Conclusion

The retraction serves as a reminder of the importance of data integrity in research.

Related Resources & Content

1. BMC Cancer, 2021 -- Retraction Notice: Comprehensive Multi-Omics Investigation
2. The ASCO Post — Genomic Profiling of Lung Adenocarcinoma in Never-Smokers vs Smokers
3. Frontiers in Immunology — Multi-omics profiling identifies ADAM9 as a key efferocytosis driver in lung adenocarcinoma
4. The ASCO Post — Genomic Profiling of Lung Adenocarcinoma in Never-Smokers vs Smokers
5. European Radiology — CT-Based Radiogenomics Evaluation of Metastatic Lung Adenocarcinoma: A Study of Single and Multi-Site Analysis and Its Impact on Patient Outcomes
6. Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1 | Journal of Clinical Oncology
7. Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC | New England Journal of Medicine
8. Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial - ScienceDirect